Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: Hepatitis C versus miscellaneous etiology

Journal of the Pakistan Medical Association

Volumn 58, Issue 11, 2008, Pages 602-607

  Abbas, Zaigham ^a   Siddiqui, Adeel Ur Rehman ^a   Luck, Nasir Hasan ^a   Hassan, Mujahid ^a   Mirza, Rashid ^a   Naqvi, Anwar ^a   Rizvi, Adibul Hassan ^a  

^a SINDH INSTITUTE OF UROLOGY AND TRANSPLANTATION   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; DELTA AGENT HEPATITIS; DISEASE COURSE; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS NON B NON C; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; PROGNOSIS; SCORING SYSTEM; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SURVIVAL ANALYSIS;

EID: 56049125738     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001; 2:533-43.
2. Verhoef C, Visser O, de Man RA, de Wilt JH, IJzermans JN, Janssen-Heijnen ML. Hepatocellular carcinoma in the Netherlands incidence, treatment and survival patterns. Eur J Cancer. 2004; 40:1530-38.
3. Bosch FX, Ribes J, Borràs J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999; 19:271-85.
4. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001; 33:62-65.
5. Colombo M. Risk groups and preventive strategies. In: Berr F, Bruix J, Hauss J, Wands J, Wittekind Ch, eds. Malignant liver tumors: basic concepts and clinical management. Dordrecht: Kluwer Academic Publishers BV and Falk Foundation; 2003. pp 67-74.
6. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362:1907-17.
7. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004 ;127 (5 Suppl 1):S35-50.
8. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005; 42:1208-36.
9. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E. et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35:421-30.
10. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19:329-38.
11. No authors listed. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology. 2000; 31:840-45.
12. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL. et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002; 94:1760-69.
13. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003; 38:207-15.
14. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H. et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985; 56:918-28.
15. No authors listed. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998; 28:751-55.
16. Levy I, Sherman M. Liver cancer study group of the University of Toronto. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging system in a cohort of 257 patients in Toronto. Gut 2002; 50:881-85.
17. Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y. et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology. 2001; 34:529-34.
18. Sørensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer. 1993; 67:773-75.
19. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996; 32A:1135-41.
20. Khokhar N, Aijazi I, Gill ML. Spectrum of hepatocellular carcinoma at Shifa International Hospital, Islamabad. J Ayub Med Coll Abbottabad. 2003; 15:1-4.
21. Nabulsi, MM., El-Saleeby, CM., Araj, GF. Lebanese Hepatitis B Collaborative Study Group. The current status of hepatitis B in Lebanon. Lebanese Medical Journal, 2003; 51: 64-70.
22. Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F. et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002; 224 :47-54.
23. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B. et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005; 54:411-18.
24. Kim JH, Choi MS, Lee H, Kim do Y, Lee JH, Koh KC. et al. Clinical features and prognosis of hepatocellular carcinoma in young patients from a hepatitis B-endemic area. J Gastroenterol Hepatol. 2006; 21:588-94.